The uterine epithelium of mice and humans undergoes cyclical waves of cell proliferation and differentiation under the regulation of estradiol-17β (E 2 ) and progesterone (P 4 ). These epithelial cells respond to E 2 with increased protein and DNA synthesis, whereas P 4 inhibits only the E 2 -induced DNA synthetic response. Here we show that E 2 regulates protein synthesis in these epithelial cells through activating PKC that in turn stimulates ERK1/2 to phosphorylate and thereby activate the central regulator of protein synthesis mechanistic target of rapamycin (mTOR). This mTOR pathway is not inhibited by P 4 . Inhibitor studies with an estrogen receptor (ESR1) antagonist showed the dependence of this mTOR pathway on ESR1 but that once activated, a phosphorylation cascade independent of ESR1 propagates the pathway. E 2 also stimulates an IGF1 receptor (IGF1R) to PI3 kinase to AKT to GSK-3β pathway required for activation of the canonical cell cycle machinery that is inhibited by P 4 . PKC activation did not stimulate this pathway nor does inhibition of PKC or ERK1/2 affect it. These studies therefore indicate a mechanism whereby DNA and protein synthesis are regulated by two ESR1-activated pathways that run in parallel with only the one responsible for the initiation of DNA synthesis blocked by P 4 . Inhibition of mTOR by rapamycin in vivo resulted in inhibition of E 2 -induced protein and DNA synthesis. Proliferative diseases of the endometrium such as endometriosis and cancer are common and E 2 dependent. Thus, defining this mTOR pathway suggests that local (intrauterine or peritoneal) rapamycin administration might be a therapeutic option for these diseases.
The uterine epithelium of mice and humans undergoes cyclical waves of cell proliferation and differentiation under the regulation of estradiol-17β (E 2 ) and progesterone (P 4 ). These epithelial cells respond to E 2 with increased protein and DNA synthesis, whereas P 4 inhibits only the E 2 -induced DNA synthetic response. Here we show that E 2 regulates protein synthesis in these epithelial cells through activating PKC that in turn stimulates ERK1/2 to phosphorylate and thereby activate the central regulator of protein synthesis mechanistic target of rapamycin (mTOR). This mTOR pathway is not inhibited by P 4 . Inhibitor studies with an estrogen receptor (ESR1) antagonist showed the dependence of this mTOR pathway on ESR1 but that once activated, a phosphorylation cascade independent of ESR1 propagates the pathway. E 2 also stimulates an IGF1 receptor (IGF1R) to PI3 kinase to AKT to GSK-3β pathway required for activation of the canonical cell cycle machinery that is inhibited by P 4 . PKC activation did not stimulate this pathway nor does inhibition of PKC or ERK1/2 affect it. These studies therefore indicate a mechanism whereby DNA and protein synthesis are regulated by two ESR1-activated pathways that run in parallel with only the one responsible for the initiation of DNA synthesis blocked by P 4 . Inhibition of mTOR by rapamycin in vivo resulted in inhibition of E 2 -induced protein and DNA synthesis. Proliferative diseases of the endometrium such as endometriosis and cancer are common and E 2 dependent. Thus, defining this mTOR pathway suggests that local (intrauterine or peritoneal) rapamycin administration might be a therapeutic option for these diseases.
estrogen | protein synthesis | mTOR | protein kinase C | DNA synthesis P rotein synthesis is coupled with the initiation of DNA synthesis with the former defining the rate of the latter. Thus, in cultured cells, alterations in the rate of protein synthesis directly alter the rate of DNA synthesis. This coupling allows the doubling of cell mass before division (1, 2) . Of course there are exceptions, for example, in cells that respond by hypertrophy without division such as muscle cells. The exact mechanisms whereby these links between protein and DNA synthesis are controlled are poorly understood although the regulatory step is known to be localized to the G1 phase of the cell cycle before a commitment point called the "R" or "transition point" (3, 4) . This link at least in part involves the expression of cyclins and their cyclin-dependent kinases whose concentrations or nuclear activity are increased and decreased throughout the cell cycle (5) . These cyclins control the activity of cell cycle genes involved in S phase through the alleviation of gene repression by the retinoblastoma (RB) family of proteins (5) . However, such simple control models are insufficient to explain the stochastic nature of DNA synthesis initiation nor its tight coupling to overall rates of protein synthesis (4) .
In the mouse and human uterus the female sex steroid hormones estradiol-17β (E 2 ) and progesterone (P 4 ) acting through their transcription factor receptors orchestrate a precise program of cell division and differentiation that is essential for embryo attachment and implantation and therefore species propagation (6) . In the uterine luminal and glandular epithelium, E 2 synthesized at proestrus in mice or the proliferative phase of the menstrual cycle in humans, causes DNA synthesis and cell division (7) . P 4 synthesized in mice in response to copulation or in humans during the secretory phase, completely inhibits this E 2 -induced DNA synthesis and cell proliferation (7) . Mechanistically in the mouse uterine epithelium, two parallel pathways have been defined that are essential for DNA synthesis and stimulated by E 2 and inhibited by P 4 . The first of these is a paracrine signaling mechanism via stromal synthesized insulin-like growth factor 1 (IGF1) that acts on the epithelial IGF1 receptor (IGF1R) to activate PI3-kinase leading to an inhibitory phosphorylation at Ser9 on glycogen synthase kinase 3β (GSK-3β) by AKT. This pathway results in cyclin D/cyclin-dependent kinase 4 (CDK4) complexes being retained in the nucleus and thereby activating the canonical cell cycle machinery by phosphorylation of RB family members (8) . The second pathway leads to DNA replication licensing through control of the activity of the hexameric minichromosome maintenance (MCM) protein preinitiation complex (9) . In part, this is through the induction of the Kruppel-like transcription factor 4 (KLF4) that transcriptionally activates MCM2 (10) . Both of these pathways are inhibited by P 4 pretreatment thereby resulting in inhibition of DNA synthesis. In the first pathway, P 4 inhibits activation of PI3-kinase and therefore AKT, resulting ultimately in maintenance of the phosphorylation of RB and inhibition of genes required for DNA synthesis. In the second case, P 4 inhibits KLF4 expression and induces expression of a second KLF transcription factor, KLF15 that binds to the MCM2 promoter among others,
Significance
Estrogen exposure is the major risk factor for diseases of the endometrium such as endometriosis and endometrial cancer. This is thought to be through its constant stimulation of epithelial cell proliferation. Progesterone blocks the estrogeninduced cell proliferation and exposure to it mitigates the risk for these diseases. However endometriotic tissue and cancer become progesterone resistant. Here we identify an estrogen induced pathway in uterine epithelial cells that activates protein synthesis through mechanistic target of rapamycin (mTOR) in a progesterone independent way. This indicates how protein and DNA synthesis regulation can be differentially controlled in vivo as progesterone blocks only the latter response. Inhibition of mTOR by rapamycin blocked E 2 -induced protein and DNA synthesis, suggesting that it might be a therapeutic target for these diseases. This article is a PNAS Direct Submission. 1 To whom correspondence should be addressed. Email: jeff.pollard@ed.ac.uk. thereby inhibiting its expression. This induction of KLF15 results in inhibition of DNA replication licensing (10) . P 4 exposure is absolutely required for the differentiation of the uterine epithelium to become receptive to the implanting blastocyst. In mice, this occurs at day 4.5 of pregnancy when a burst of E 2 synthesis opens the so-called "window of receptivity" allowing the blastocyst to attach (6). This P 4 E 2 regimen also results in a strong stimulation of protein synthesis that is quantitatively similar to the stimulation seen with E 2 treatment alone. This stimulation of protein synthesis under both hormonal regimens is caused by increased rates of ribosome biosynthesis and enhanced translational initiation (11) . Indeed cell growth is equivalent in the epithelial cells under E 2 or P 4 E 2 treatment until cell division reduces the cell mass by 50% in the E 2 -treated group. These data raise the conundrum of how E 2 stimulates protein and DNA synthesis, whereas P 4 only inhibits DNA synthesis. Elucidation of this mechanism might provide insight into mechanisms of coupling protein synthesis to DNA synthesis.
In mammalian cells, protein synthesis is largely regulated through the mechanistic, also known as mammalian, target of rapamycin (mTOR) pathway. In the center of this pathway, mTOR acts as a regulatory hub receiving signals that respond to growth factors and nutrient availability to coordinate growth, proliferation, and maintenance of homeostasis (12) . mTOR nucleates the mTORC1 and -2 complexes with the former being the major regulator of protein synthesis. When mTOR is phosphorylated by upstream kinases, it phosphorylates the translational regulators, eukaryotic translational initiation factor 4E (eIF4E) binding protein 1(EIF4EBP1), and ribosomal S6 kinase 1 (RPS6K1) (13) . This pathway promotes an increase in the rate of global translational initiation by phosphorylation of RPS6 and the alleviation of the inhibition by EIF4EBP1 on eIF4E. mTORC1 also activates many genes through a variety of mechanisms that promote anabolism (13) . This mechanism therefore allows global increase in lipid, protein, and carbohydrate metabolism that in turn allows cells to proliferate.
Growth factor signaling to mTOR is often through activation of AKT (PKB) (13) . However, in the uterine epithelium, AKT, while stimulated by E 2 , is inhibited by P 4 E 2 treatment (14), suggesting this is not a regulatory mechanism for protein synthesis in the uterine epithelial cells. In this study therefore we hypothesized that there is another E 2 -induced pathway unaffected by P 4 treatment that is activated in parallel with the PI3-kinase to the AKT one. Here we show that such a P 4 -independent pathway is present in the uterine epithelium with E 2 signaling via phospho-kinase C (PKC) to extracellular signal-regulated kinases 1 and 2 (ERK1/2) to mTOR thereby stimulating protein synthesis. Furthermore we show that inhibition of this pathway had significant physiological consequences including blockage of DNA synthesis.
Results

E 2 Induces mTOR Signaling Independent of P 4 and This Is Required for
Stimulation of Protein Synthesis. E 2 induces uterine epithelial cell growth by stimulating protein synthesis at the initiation step and later by increasing the cellular concentration of ribosomes through increased rRNA transcription (11) . In addition, it stimulates DNA synthesis and cell division, resulting in an increase in cell number (8) . P 4 inhibits this E 2 -induced DNA synthetic response but the E 2 -induced increase in protein synthetic rate is unaffected by this hormone. To determine the molecular basis of this differential response, we studied activation of protein synthesis initiation through the mTOR pathway.
First we examined the effect of E 2 on the mTOR pathway and whether this regulation was influenced by P 4 . Western blots of uterine epithelial cell extracts isolated at different times after exposure to E 2 in the presence or absence of P 4 were analyzed for changes in phosphorylation states of the components of this pathway (Fig. 1A) . As indicated by the binding of phospho-specific antibodies, E 2 significantly increased the phosphorylation of the ribosomal protein S6 (RPS6) at Ser235/236 and 240/244 with an elevation found at 2-4 h after treatment and continuing through to 8 h ( Fig. 1 A and B) . Total RPS6 protein was unaffected by the hormonal treatment. Phosphorylation of RPS6 is considered to be the canonical readout of the mTOR pathway and is associated with an increase in protein synthesis. Consistent with this increased phosphorylation, the activating phosphorylation of RPS6K1 at Ser424 and Thr389 was also elevated by E 2 treatment. E 2 also increased with similar kinetics, phosphorylation of other members of the pathway, the phosphorylation of EIF4B at Ser406, EIF4EBP1 at Thr70, as well as mTOR itself at Ser2481 (Fig. 1 A and B) . These responses were both kinetically and quantitatively similar in the luminal epithelia isolated from mice that had been exposed to P 4 E 2 ( Fig. 1 A and B) . The total protein level of RPS6 and EIF4EBP1 were not changed after normalization to β-tubulin, indicating that the percentages of these proteins per total protein were not influenced by the hormonal treatment. Thus, we can conclude that E 2 stimulates independent of P 4 the canonical mTOR pathway leading to RPS6 and EIF4EBP1 phosphorylation consistent with the E 2 effects on protein synthesis initiation.
To determine whether this pathway could also be found in human endometrial tissue in response to E 2 and the effect of P 4 , we used two approaches. The first was to obtain endometrial biopsies from the proliferative phase (E 2 dominated) and secretory phase (E 2 and P 4 high) of reproductive age women ( Fig.  1 C, i ) and used phospho-specific antibodies to detect RPS6 and mTOR phosphorylation by immunohistochemistry (IHC). Consistent with the data obtained in mice, immunostaining indicated phospho-mTOR and -RPS6 present in the luminal and glandular epithelium of human endometrium and, whereas the immunostaining was variable from region to region, over samples obtained from three volunteers per menstrual cycle phase, the staining was similar in proliferative and secretory phases ( Fig. 1 C, ii) . To confirm this result, we determined the staining intensity by the H-score method and found that there was no significant difference in staining between the two phases of the menstrual cycle ( Fig. 1 C, iv) .
The second approach was to examine human endometrial tissue that had been xenotransplanted under the kidney capsules of ovariectomized immunocompromised mice (15) . These transplants grow over a period of 3 mo with E 2 supplementation into recognizable endometrial structures and following removal of the E 2 pellets become hormone responsive and mimic the proliferative responses found in the human menstrual cycle (Fig. 1 C, i) . Thus, we supplemented the xenografted mice with regimens of E 2 and P 4 E 2 and harvested the xenotransplants 6 h after the last E 2 treatment and processed them for IHC. Control untreated grafts had minimal staining for phospho-mTOR or phospho-RPS6 ( Fig. 1 C, iii) . However, treatment with E 2 for 6 h showed an increase in staining for phospho-mTOR and phospho-RPS6 ( Fig. 1 C, iii) and over three to five different xenotransplants, there was no apparent difference between the stimulation by E 2 with or without P 4 treatment. Using the H-score method, minimal staining was detected in the hormone-depleted group. However, following E 2 treatment, there was a significant and dramatic increase in staining intensity. This level of immunostaining for phospho-mTOR or phospho-RPS6 was unaffected by P 4 treatment ( Fig. 1 C, iv) . Thus, we can conclude in the human endometrial epithelium that E 2 stimulates the mTOR pathway independent of the presence of P 4. To test whether mTOR is the mediator of signaling from E 2 to the protein synthetic machinery in mice, we inhibited mTOR activity with the canonical mTOR inhibitor, rapamycin (16) . To obtain specificity in the uterus, we injected this drug at 10 μM into the uterine lumen 30 min before E 2 injection (Fig. 2 A, i ). This treatment inhibited E 2 -induced mTOR phosphorylation although at this concentration not completely in both E 2 -and P 4 E 2 -treated groups ( Fig. 2 A, ii and iii). This treatment also inhibited phosphorylation of RPS6K1 and RPS6 to similar extents ( Fig. 2 A, ii and iii). Phosphorylation of ERK1/2, a molecule that does not receive direct regulation from mTORC1 (see below), was unaffected by the rapamycin treatment ( Fig. 2 A, ii and iii). Rapamycin thus inhibits the mTOR pathway in the uterine epithelium.
To examine the effect of mTOR inhibition on the E 2 -induced protein synthesis, we performed two sets of experiments to determine the rate of incorporation of radioisotope-labeled amino acids into de novo synthesized protein. In one set of experiments ( Fig. 2 B, i) , rapamycin was injected into the uterine lumen in vivo 30 min before E 2 treatment and the protein synthetic rates were determined ex vivo 2 h after hormone treatment using methods previously described (11) . In the other experiment, rapamycin was added into the ex vivo culture medium containing uteri harvested 2 h after hormone treatment without rapamycin administration ( Fig. 2 B, ii) . In both experiments, protein synthesis was measured by isotopic incorporation of labeled amino acids into acid insoluble protein ex vivo for 6 h. We found that the incorporation rate is significantly increased in the uterine epithelium after E 2 treatment in both sets of experiments as previously observed (11) . Rapamycin inhibited this stimulation of protein synthesis in both cases ( Fig. 2 B, i and ii). These data confirm that E 2 -induced mTOR activation is responsible for the stimulation of the protein synthesis rate in the uterine epithelium.
Physiological Consequences of mTOR Inhibition. An increase in protein synthesis is also expected to be required for E 2 -induced DNA synthesis. To confirm this expectation in the uterine epithelium and to test that this expectation is linked to mTOR stimulation, we inhibited mTOR with rapamycin ( Fig. 3 A, i) and determined the rate of DNA synthesis by measuring the rate of BrdU incorporation as described before (17) . The incorporation rate (percentage of positive nuclei) of BrdU in the uterine epithelium injected with PBS of control nonhormone-treated mice was less than 10% ( Fig. 3 A, ii and iii). Uterine epithelial DNA synthesis as assessed by BrdU incorporation was dramatically stimulated by E 2 with greater than 90% of cells being positive 15 h posttreatment as has been reported before (8) . This response to E 2 was completely abrogated by treatment with rapamycin given intraluminally 30 min before the E 2 treatment (Fig. 3 A, ii and iii). These data suggests that E 2 stimulates mTOR to activate protein synthesis and this pathway is required for DNA synthesis.
The stimulation of DNA synthesis also requires the activation of a paracrine pathway starting from E 2 -induced stromal synthesis of IGF1 that stimulates IGF1R in the epithelium to signal to an inhibitory phosphorylation of GSK-3β ser9 (14, 17) . It is possible that, although the rapamycin was applied intraluminally and thus directly adjacent to the epithelial surface, a sufficient concentration accumulated in the stroma to block induction of IGF1 and that this is the cause of the inhibition of DNA synthesis. Thus, we measured the expression of mRNA Igf1 in the stroma and the downstream output of this pathway GSK-3B ser9 phosphorylation in the epithelium. As previously reported mRNA Igf1 is dramatically up-regulated by E 2 ( Fig. 3 A, iv) but this induction was unaffected by the intraluminal injection of rapamycin ( Fig. 3 A, iv) . Furthermore in the uterine epithelium the E 2 -induced induction of GSK-3β ser9 was unaffected, and maybe even slightly stimulated, by rapamycin treatment (Fig. 3 A, v) . Analysis of phosphorylation of RPS6 ser235/236 indicated that the rapamycin treatment was effective as a reduction in the phosphorylation of RPS6 was observed ( Fig. 3 A, v) as found in the previous experiments. We can conclude therefore that at least at this concentration, rapamycin given intraluminally is affecting mTOR signaling in the uterine epithelium without influencing stromal IGF1 responses.
To find out whether a similar response occurs in human endometrium, we tested ( Fig. 3 B, i) whether rapamycin inhibited the E 2 stimulation of DNA synthesis in human endometrial transplants as assessed by anti-MKI67 IHC as described before (15) . E 2 significantly increased the percentage of MKI67-positive cells in the epithelial cells compared with nonhormone-treated controls (Fig. 3 B, ii and iii). In these experiments, rapamycin cannot be introduced into the lumen and thus it was administered for Fig. 1 . Analysis of the mTOR signaling pathway following E 2 and P 4 treatment. (A) Ovariectomized mice were treated in one of the following regimens: vehicle alone (ctrl), E 2 , P 4 , or P 4 E 2 . Mice were killed at the time indicated (in hours). Western blots were performed with purified uterine epithelial cell lysates to determine the phosphorylation status of components in the mTOR signaling pathway as indicated. Total protein abundance of RPS6 and EIF4EBP1 was determined by Western blotting. Detection of β-tubulin was used as a loading control. Each group in these experiments had three to five mice and each experiment was repeated six times. (B) The relative signals from the Western blots of which representative samples are shown in A were measured by densitometry and normalized for loading with the β-tubulin intensity. Mean ± SEM **P < 0.01. (C, i) Human endometrial biopsies were collected according to cycle day determined by urinary luteinizing hormone kits as indicated. (ii) The biopsies were subjected to paraffin sectioning and immunohistochemistry or (iii) embedded into kidney capsules of immunocompromised mice supplied with E 2 . (ii) Representative human biopsies obtained during proliferative and secretory phase immunostained with antibodies against p-mTOR and p-RPS6 and counterstained with hematoxylin. Each group in the experiment had three individual biopsies. (iii) Ovariectomized mice with human endometrial xenotransplants received either E 2 or P 4 E 2 regimens and were killed at 6 h after the E 2 treatment. The tissues were subjected to paraffin sectioning and immunostained with antibodies against p-mTOR and p-RPS6 (brown) and a representative experiment is shown. The experiment had three individual xenotransplants in each group with sections from three to five independently treated mice stained. (iv) H-score was determined as described in Materials and Methods and the mean of eight fields ± SEM shown. Significance was determined by a Student's t test. NS, not significant; ****P < 0.0001. 5 d intraperitoneally. This regimen inhibited the E 2 -induced increase in MKI67 cells to a level slightly lower even than the control PBS-treated group (Fig. 3 B, ii and iii) . These data suggest that mTOR activation is also required for DNA synthesis of human endometrial epithelial cells in response to E 2 . E 2 Stimulation of mTOR Is Dependent on Activation of ERK1/2. The mTOR pathway can be regulated by several different inputs that result in stimulation of the mTORC1 complex. Of these inputs, the most studied is AKT, which directly phosphorylates tuberous sclerosis complex 2 (TSC2) and disrupts the TSC1/2 complex. As a consequence, Ras homolog enriched in brain (RHEB) function is not inhibited by TSC1/2 and it can mediate an activating phosphorylation of mTOR (18) . In the uterine luminal epithelium, AKT is stimulated by E 2 but inhibited by P 4 . However, as shown above, mTOR is active under both hormonal regimens, suggesting that other mTOR regulators are likely activated by E 2 . In addition to AKT, AMPK has been reported to serve as a sensor of energy status signaling into the mTOR pathway, as it can directly phosphorylate TSC2 (19) . mTOR is also sensitive to hypoxic stress and this stress response is mediated by the binding Fig. 2 . Rapamycin inhibits activation of the mTOR pathway and protein synthesis. (A, i) Schematic procedures of rapamycin inhibition. Ovariectomized CD1 mice were treated with standard hormonal regimens as in Fig 1. A total of 50 μL of 10-μM rapamycin was injected intraluminally, a half hour before the last hormone treatment. Mice were killed at 2 h for analysis of ERK1/2 phosphorylation and 8 h for analysis of mTOR, RPS6K1, and RPS6 phosphorylation.
(ii) Uterine epithelial cell lysates were subjected to Western blotting with antibodies against phospho-mTOR, -RPS6K1, -RPS6, -EIF4EBP1, and -ERK1/2. (iii) Relative signal densities were represented as histograms. Mean ± SEM *P < 0.05; **P < 0.01. Each group in these experiments had three to five mice and each experiment was repeated three times. (B, Upper) Two groups of experiments were run in parallel. In both experiments, mice received standard hormonal regimens, uteri were collected 2 h after the last hormone treatment and incubated with isotope in culture media and incubated for 6 h. Uterine epithelial cell lysates were prepared and the protein synthesis rates determined or the lysates subjected to Western blotting (to analyze phosphorylation state of MARCKS). The expression levels of β-tubulin were analyzed as loading control for the Western blots. In experiment 1 (B, i) Inhibitors (rapamycin and/or Bis-1) were injected into the uterine lumen a half hour before hormone; in experiment 2 (B, ii) the same inhibitors were only added into the culture medium. The normalized counts per minute values for experiments i and ii are shown on the histograms. Mean ± SEM *P < 0.05; **P < 0.01. Each group in these experiments had three to five mice and each experiment was repeated three times.
of REDD1 to TSC2 (20) . In addition, the Ras-ERK pathways can also regulate mTOR by phosphorylation of TSC2 directly by ERK1/2, and through p90 ribosomal S6 kinase (p90RSK) an ERK1/2 effector (21). However, the uterus is not in a hypoxic state nor is it starved for energy or amino acids. Therefore, we hypothesized that the signaling from E 2 to mTOR is mediated by ERK1/2. Using Western blotting and phospho-specific antibodies, we detected a rapid phosphorylation of ERK1/2 within 1 h after E 2 treatment (Fig. 4A) . This stimulation had returned to control levels by 4 h. E 2 also stimulated ERK1/2 phosphorylation in the presence of P 4 with a similar kinetic, although with a slightly lower amplitude. The increase in phospho-ERK1/2 following E 2 treatment in the presence or absence of P 4 coincided with activation of the mTOR pathway and temporally was before the stimulation of phospho-RPS6, suggesting it might be the upstream regulator of this pathway. To test whether such rapid activation of ERK1/2 is required for mTOR/RPS6 activation, we used the MEK1/2 inhibitor PD184352 at 500 nM introduced intraluminally into the uterus 30 min before hormone injection and determined its effect on the mTOR pathway. Fig. 2A . BrdU was injected intraperitoneally 13 h after the last hormone treatment. Mice were killed 2 h thereafter. The uteri were collected for paraffin sectioning. BrdU immunostaining (brown) was performed on cross-sections of untreated (control), E 2 -treated, and E 2 + rapamycintreated uterus and were counterstained with hematoxylin. (ii) Histology of representative transverse sections of uteri immunostained for BrdU as described in i.
(iii) The percentage of BrdU-positive luminal epithelial cells was calculated. Mean ± SEM ***P < 0.001. Each group in these experiments had three or four mice and each experiment was repeated three times. (iv) Uterine stromal cells were prepared at 4 h and RNA was isolated for RT-PCR. cDNA was used as template to determine the expression level of Igf1. The relative signal intensity was normalized against Gapdh as loading control. (v) Uterine epithelial cell lysates from mice with treatments shown in iv were prepared at 8 h as described above and subjected to Western blot with antibodies against phospho-GSK-3β Ser9 , RPS6 Ser235/236, and β-tubulin. Each experiment in iv and v was performed in duplicate with three to four mice per group. (B, i) Human endometrial tissue was established as a xenotransplant in mice as described in Fig. 1C . Rapamycin was injected intraperitoneally for 5 consecutive days before the last hormone treatment. The mice were killed 15 h after the last hormone treatment at the peak of E 2 -induced DNA synthesis and their uteri were subjected to paraffin sectioning, and sections were then immunostained with anti-MKI67 antibodies and counterstained with hematoxylin. (ii) Representative cross-sections showing immunostaining for MKI67 following the treatments shown. (iii) Percentage of MKI67 positive cells is shown in the histograms. Mean ± SEM ***P < 0.001. These experiments had five individual xenotransplants in each group and staining was repeated three times.
PD184352 inhibited the increased phosphorylation of ERK1/2 in the epithelial cells. This inhibition by PD184352 resulted in a significant drop in the level of phosphorylation of p90RSK, mTOR, RPS6K1, and RPS6 (Fig. 4B) . These data suggest that ERK1/2 is required for the activation of the mTOR pathway.
PKC Is Necessary and Sufficient for mTOR Pathway Activation in the
Uterine Epithelium. PKC is an upstream regulator of ERK1/2 and is activated by P 4 E 2 treatment (22) . Thus, we hypothesized that PKC activates the mTOR pathway following E 2 treatment. To test this hypothesis, we first determined the individual PKC isoforms expressed in the uterine epithelium by RT-PCR of RNA isolated from uterine epithelial cells. We detected expression of PKC α, β2, δ, and η (Fig. 5 A, i) . The expression level of transcripts for these PKC isoforms was similar in control, E 2 , P 4 , and P 4 E 2 groups, suggesting that changes in transcript abundance are not the level of regulation if any, of these enzymes.
Secondly we tested the effects of E 2 on the stimulation of PKC using the phosphorylation level of myristoylated alanine-rich C-kinase substrate (MARCKS) as an activity readout measured by phospho-specific antibody binding to Western blots of lysates of the luminal epithelial cells. Increased phospho-MARCKS at Ser167/170 was detected within 2 h of E 2 administration to the mice and this persisted for at least 8 h (Fig. 5 A, ii and iii) . Administration of P 4 did not change this pattern of E 2 stimulation of MARCKS phosphorylation (Fig. 5 A, ii and iii) . This induction is consistent with ERK1/2 activation (Figs. 4A and 5 A, ii and iii) and subsequent stimulation of phosphorylation of mTOR and RPS6 as we demonstrated above and also shown in Fig. 5 A, ii and iii. This experiment indicated that PKC was activated by E 2 independently of P 4 and its activation is kinetically consistent with stimulation of the mTOR pathway and protein synthesis.
To test the necessity of PKC in the mTOR activation we inhibited its activity with the ATP binding site competitive inhibitor Bis-1 (23). First we optimized the concentration of Bis-1 given intraluminally, which was needed to inhibit PKC as assessed by phosphorylation of MARCKS. Because all of the PKC inhibitors have some off-target effects, we chose the concentration of 1 μM, which inhibited PKC, but did not inhibit GSK-3β, thus allowing us to discriminate Bis-1's effects on PKC from AKT, which is (A) Uterine epithelial cell lysates were prepared following hormone treatment at indicated time points. The lysates were subjected to Western blotting with antibodies against phospho-ERK1/2, -mTOR, and -RPS6. β-Tubulin expression was used as a loading control. Signal densities of phospho-ERK1/2, -mTOR, and -RPS6 were measured and normalized with β-tubulin and represented by the histograms. Mean ± SEM *P < 0.05; ***P < 0.001. Each group in these experiments had three to five mice per group and each experiment was repeated three times. (B) Thirty minutes before the last hormone treatment, 50 μL of the 500 nM ERK1/2-specific inhibitor PD184352 was injected intraluminally to determine the necessity of ERK1/2 activity for the mTOR pathway. Uterine epithelial lysates were prepared at 2 h to analyze phosphorylation states of ERK1/2 and at 8 h to analyze phosphorylation states of p90RSK, mTOR, RPS6K1, and RPS6. Signal intensities were normalized with β-tubulin expression and displayed as histograms. Mean ± SEM *P < 0.05. Each group in these experiments had three to five mice per group and each experiment was repeated three times.
another E 2 -regulated pathway. Bis-1 was injected intraluminally into the uterus at 1 μM 30 min before hormone treatment to give tissue specificity to its inhibition. Bis-1 inhibited the E 2 -stimulated hyperphosphorylation of MARCKS at all times after E 2 treatment regardless of whether the mice were treated with P 4 (Fig. 5 A, ii and iii) . Furthermore Bis-1 inhibited phosphorylation of mTOR (2-8 h), RPS6 (2-8 h), and ERK1/2 (2 h), although the total expression level of these proteins was not changed (Fig. 5 A, ii) . Thus, PKC inhibition blocked the E 2 -induced stimulation of the mTOR pathway and indicates PKC activity is required for the effect of E 2 on this pathway. The intraluminal injection of Bis-1 also inhibited the E 2 -induced stimulation of protein synthesis as measured by the incorporation of radioactively labeled amino acids (Fig. 2 B, i) regardless of P 4 treatment, consistent with its inhibition of mTOR phosphorylation. However, when Bis-1 was added to the incubation media of uteri that had been stimulated by E 2 for 2 h in vivo, despite its inhibition of phosphorylation of MARCKS, it failed to inhibit protein synthesis (Fig. 2 B, ii) . These data are consistent with PKC activation being transient and upstream of protein synthesis activation via mTOR.
Next to further test our hypothesis, we asked whether PKC activation was sufficient to stimulate the mTOR pathway by intraluminally injecting the PKC agonist phorbol-12-myristate-13-acetate (PMA), which mimics the lipid second messenger Fig. 5 . PKC is necessary and sufficient for mTOR activation. (A, i) Eight hours after hormonal regimens, total RNA from uterine epithelial cells was prepared following procedures described in Materials and Methods. RT-PCR was performed and bands were visualized after separation on 2% (wt/vol) agarose gels. PKCα, β2, δ, and η were successfully amplified to equal cycles between different hormone treatments and a representative gel is shown. Each group in these experiments had three to five mice and each experiment was repeated three times. (ii) A total of 50 μL Bis-1 was injected intraluminally at the concentration of 1 μM, a half hour before the last hormone treatment. Protein lysates were prepared at 2, 4, and 8 h after the last hormone treatment and subjected to Western blots to determine the phosphorylation status of MARCKS, mTOR, RPS6, ERK1/2, and GSK-3β with corresponding antibodies. Protein abundance of mTOR, RPS6, and ERK1/2 was also determined to analyze their expression levels. Each group in these experiments had three to five mice and each experiment was repeated four times. (iii) Relative signal intensities from the Western blots were measured, normalized by expression levels of β-tubulin, and represented by the histograms. Mean ± SEM, NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001. (B, i) A total of 50 μL of 1-μM PMA was injected intraluminally into the uterine lumen, a half hour before the last hormone treatment. Protein lysates of uterine epithelial cells from three independent replicates were prepared at 8 h after the last hormone treatment and subjected to Western analysis for phosphorylation status of MARCKS, RPS6, and GSK-3β. (ii) Relative signal intensities were measured and represented by the histograms. Mean ± SEM NS, P > 0.05; *P < 0.05. Each group in these experiments had three to five mice and each experiment was repeated three times. (iii) Mice received the following treatment as indicated: 50 μL PBS intraluminal injection (ctrl); sham operation (sham); 50 μL intraluminal injection of 1-μM PMA (PMA); coinjection of 50 μL 1-μM PMA and 500 nM PD184352 into the uterine lumen (PMA + PD); intraluminal injection of 50 μL 1-μM PMA followed by the last injection of the E 2 regimen; and coinjection of 50 μL 1-μM PMA and 500 nM PD184352 into the uterine lumen followed by the last injection of the E 2 regimen. Protein lysates were prepared from duplicate treatment groups at 8 h after the last hormone treatment and subjected to Western blots with antibodies against phospho-RPS6 and GSK-3β. (iv) Relative signal intensities relative to β-tubulin were measured and represented by the histograms. Mean ± SEM NS, P > 0.05; *P < 0.05; **P < 0.01. Each group in these experiments had three to five mice and each experiment was repeated three times. (C, i) Mice received treatments as indicated: intraluminal injection of DMSO (control); ICI182780 injection; intraluminal injection of PMA; E 2 alone; PMA and ICI182780 treatment; ICI182780 treatment and the E 2 regimen; PMA injection and the E 2 regimen; and PMA and ICI182780 treatment together with the E 2 regimen. In the ICI-treated groups, 5 mg ICI182780 was injected intraperitoneally 1 h before the E 2 treatment was given s.c. (ii) Uterine epithelial lysates were prepared at 8 h after the last hormone treatment and subjected to Western blots with antibodies against phospho-RPS6 and β-tubulin. Each group in these experiments had three to five mice and each experiment was repeated three times. (iii) Signal intensities were measured and normalized to β-tubulin and represented by the histograms. NS, P > 0.05; *P < 0.05; **P < 0.01. Each group in these experiments had three to five mice and each experiment was repeated three times. diacylglycerol (DAG) (24) . In the absence of steroid hormone treatment, injection of PMA alone induced PKC activity as indicated by increased phosphorylation at Ser 167/170 of the PKC reporter MARCKS (Fig. 5 B, i and ii) . This PMA-induced activation of PKC was sufficient to stimulate the Ser 235/236 phosphorylation of RPS6 in the luminal epithelial cells to an even higher level than E 2 treatment (Fig. 5 B, i and ii) .
To determine whether ERK1/2 and PKC were in a linear pathway, we injected both PMA and PD184352 intraluminally into the uterus (Fig. 5 B, iii and iv) . Concordant with our previous results (Fig. 5 B, i and ii) , PMA resulted in a high phosphorylation level of RPS6 (Fig. 5 B, iii and iv) . However, this increase was inhibited by PD184352 coadministration (Fig. 5 B, iii and iv), suggesting that PKC is upstream of ERK1/2 activation and RPS6 phosphorylation. Together these data strongly support the hypothesis that E 2 stimulates PKC, which in turns activates ERK1/2, which results in phosphorylation of mTOR, which then stimulates protein synthesis.
mTOR Activation Is Independent of AKT. Our previous data showed that E 2 induces a signaling pathway from PI3-kinase to AKT, resulting in GSK-3β inactivation due to phosphorylation at Ser9 and consequently cyclin D1 nuclear localization (14) . This pathway was blocked by P 4 and is part of the mechanism whereby P 4 inhibits E 2 -induced DNA synthesis. As AKT can regulate mTOR activity and has been reported to either activate (25) or inhibit (26) PKC dependent on condition, we questioned whether this pathway might be affected by PKC activation and therefore be partially responsible for the mTOR activation. To test this hypothesis, we examined GSK-3β phosphorylation at Ser9 in parallel with phosphorylation of RPS6 following PKC activation or inhibition. As previously described, E 2 leads to robust phosphorylation of GSK-3β Ser9 beginning at 2 h posttreatment and persisting to 8 h (Fig. 5 A, ii and iii and B, i and ii) after treatment and this increase is coincident with the phosphorylation of RPS6. Inhibition of PKC with Bis-1, whereas inhibiting the increased phosphorylation of the mTOR pathway, does not influence the E 2 -induced phosphorylation of GSK-3β Ser9 (Fig. 5 A, i and ii) . In addition, as we previously demonstrated, P 4 inhibits this GSK-3β
Ser9 phosphorylation but as shown above, it does not interfere with the activation of the mTOR pathway (Fig.  5 A, ii and iii) and there is also no activation of GSK-3β after Bis-1 treatment as expected (Fig. 5 A, ii and iii) . We examined the effect of PKC activation by PMA where there is robust phosphorylation of RPS6 and found no increase in phosphorylation of GSK-3β ser9 (Fig. 5 B, iii and iv), indicating that this latter pathway is not influenced by a PKC-mediated mechanism. In addition, the E 2 -induced GSK-3β ser9 phosphorylation was not affected by inhibition of ERK1/2 by PD184352 introduced intraluminally (Fig.  5 B, iii and iv) . However, PD184352 in these experiments did not entirely inhibit the RPS6 phosphorylation caused by PKC activation, raising the possibility that there may be another pathway regulating mTOR phosphorylation. Nevertheless and regardless of this alternative possibility, together these data are consistent with a pathway of PI3-kinase leading to GSK-3β, which is differentially regulated by E 2 and P 4 and independent of PKC. Furthermore, these two pathways transduce signals to their own targets in parallel, giving spatial and temporal control over protein and DNA synthesis in the uterine epithelium.
ESR1 Activity Is Required for PKC Activation. The effects of E 2 in the uterus on cell growth and proliferation are mediated by the estrogen receptor, ESR1 (27) . However, significant evidence suggests that its actions on the uterine epithelium are through paracrine mechanisms. In these cases, once the estrogen receptor is engaged by E 2 , it initiates a signaling cascades that is independent of ESR1 (17, 28) . Thus, to determine if the PKC pathway requires ESR1 only at the initiation of the pathway or during its signaling, we used the pure ESR1 antagonist, ICI182780, to inhibit uterine E 2 signaling (17) followed by measurement of phospho-RPS6 as a readout (Fig. 5 C, i) . ICI182780 did not affect basal phospho-RPS6 levels nor those stimulated by PMA that had been given intraluminally. However, as expected ICI182780 did inhibit E 2 -induced phospho-RPS6, showing the requirement of ESR1 for this signaling event (Fig. 5 C, ii and iii) . In contrast, E 2 given in combination with PMA stimulated phospho-RPS6 signaling but this stimulation was unaffected by ICI182780 (Fig. 5 C, ii  and iii) . Thus, even in the presence of inhibited ESR1, PMA induced signaling to RPS6. These data suggest that PKC is downstream of ESR1, and that physiologically PKC activation requires the functionality of ESR1. Furthermore, PMA and E 2 did not have significantly additive effects, suggesting that there is only one pathway downstream of E 2 (Fig. 5C ).
Discussion
Coordinated regulation of protein and DNA synthesis is required for successful cell division. Thus, these events are intimately linked with the former regulating the rate of a cell's entry into DNA synthesis. Tissues such as the uterus that cyclically respond to E 2 with cell division and differentiation dependent on the presence or absence of P 4 provides a model of how such processes are regulated in vivo. In this study, we have defined a PKC-mediated pathway activating mTORC1 through ERK1/2 that stimulates protein synthesis (Fig. 6) . Activation of this pathway requires E 2 binding to its receptor, ESR1, although whether this requirement is paracrine or autocrine remains to be determined. However, once initiated, the pathway becomes independent of this receptor and the signal is propagated by a phosphorylation cascade. Inhibition of mTOR by rapamycin blocked E 2 -induced protein synthesis confirming its dependence on the mTOR pathway in these epithelial cells. mTOR inhibition also had significant physiological consequences as it blocked E 2 -induced DNA synthesis in both the mouse and human endometrial epithelium. Model for E 2 -induced signal transduction pathways in the uterine epithelium leading to DNA and protein synthesis. E 2 binds to its receptor, ESR1, thereby conveying a signal to stimulate DNA and protein synthesis in the uterine epithelium. In the case of DNA synthesis, this is through an IGF1-mediated paracrine pathway (dotted red line indicates the interface between stromal and epithelial cells) that results in cyclin D1 being accumulated in the epithelial nuclei. This pathway is inhibited by P 4 (14) . At the same time E 2 stimulates another pathway in either an autocrine or paracrine manner, which remains to be determined via PKC to mTOR to stimulate protein synthesis. This PKC-stimulated pathway runs in parallel to the IGF1-mediated one but unlike the IGF1R pathway, this pathway is not inhibited by P 4. Nevertheless it too is required for successful entry into DNA synthesis following E 2 stimulation.
These data show in an epithelial cell in vivo how DNA synthesis can be independently regulated from protein synthesis (Fig. 6 ). In the former case, E 2 regulates stromal IGF1 synthesis that activates IGF1R expressed in the epithelial cells to signal through PI3-kinase to AKT to cause nuclear accumulation of cyclin D1 through an inactivating phosphorylation of GSK-3β, a kinase that phosphorylates cyclin D1 and causes its nuclear egress (14) . AKT in many cell culture models regulates mTOR activity (12) . However, in the uterine epithelium, P 4 inhibits AKT activation by E 2 , thereby inhibiting DNA synthesis (14) . Instead E 2 stimulates protein synthesis via the PKC pathway described above. This PKC pathway is sequestered from the AKT pathway. This sequestering was shown by inhibition of PKC or ERK1/2 that blocked mTOR activation but left GSK-3β ser9 phosphorylation untouched, whereas activation of the pathway by PMA did not cause GSK-3β ser9 phosphorylation. Nevertheless, both pathways required ESR1 binding by E 2 that then stimulates the two parallel pathways that are differentially regulated by P 4 .
PKC is required for activation of the mTOR pathway within the first 2 h when ERK1/2 is activated, a time that coincides with maximal ESR1 receptor occupancy in vivo (29) . ERK1/2 phosphorylation decreases to basal level at 4 h and 8 h, whereas the activity of the mTOR pathway and rate of protein synthesis are relatively high. However, inhibition of ERK1/2 is sufficient to block this 4 h and 8 h mTOR activity, indicating that the early phosphorylation of ERK1/2 is necessary for persistent mTOR phosphorylation. Early activation of the PKC pathway was demonstrated by experiments whereby epithelial protein synthesis was inhibited by an intraluminal injection of the PKC inhibitor Bis-1 applied before E 2 treatment, whereas a similar treatment when Bis-1 was added 2 h after E 2 to the culture medium failed to inhibit protein synthesis despite inhibition of PKC signaling to MARCKS. In contrast to this transient requirement for PKC, rapamycin inhibited protein synthesis when injected intraluminally or after incorporation into the culture medium, indicating a continued need for mTOR activity. PKC activation, however, was not transient but persisted for at least 8 h post-E 2 treatment either in the presence or absence of P 4 . We had previously demonstrated (22) the PKC induction in the P 4 E 2 -treated luminal epithelium of the immune response gene1 (Irg1), suggesting that PKC has functions in the luminal epithelial cells other than regulating protein synthesis.
Uterine cell growth and proliferation are tightly regulated every estrus or menstrual cycle (7) . In the menstual cycle in women, the functionalis layer of the endometrium undergoes regeneration of the uterine structure in a process of scarless healing that is driven by E 2 . These uterine tissues are very resilient but as women age there is an increased risk of epithelial hyperplasia that can lead to endometrial cancer (30) . In fact, endometrial cancer was responsible in 2013 for ∼50,000 new cases and 8,000 deaths in the United States, and its incidence is increasing. Heightened mTOR signaling has been detected in endometrial cancers and in mouse models of these malignancies (31) . It has been suggested that this activation is downstream of AKT whose activity is aberrantly up-regulated as a consequence of the PI3 kinase activation due to pTEN loss frequently seen in these cancers (31) . Here we show this mTOR pathway is also regulated by PKC, suggesting the possibility of alternative means of activation to AKT in human endometrial cancer. We also show that rapamycin can inhibit E 2 -induced DNA synthesis, suggesting that such treatments may be efficacious in endometrial cancer, as was found recently in mouse models of this cancer (31) . Indeed, the mTOR inhibitor temsirolimus IV is in early phase clinical trials for this indication (www.clinicaltrials.gov). Furthermore, endometriosis, a benign condition affecting 6-10% of women, associated with considerable morbidity, is marked by E 2 -induced cell proliferation and P 4 resistance (32), suggesting that mTOR inhibition might also be useful therapeutically in this disease.
Materials and Methods
Animal Treatment. Hormonal regimens. Female CD1 mice at 6-8 wk of age (Charles River Laboratories) were ovariectomized and rested for 2-3 wk before hormone treatment. E 2 and P 4 (Sigma Chemical) were diluted in peanut oil and injected s.c. in regimens designed to mimic the physiological situation as described before (8) . Briefly, mice were primed with 100 ng of E 2 for 2 d, rested for 2 d, and then randomly divided into four groups. Groups were treated as follows: (i) oil alone given only on day 6 (control), (ii) one s.c. injection of 50 ng of E 2 on d 6, (iii) 4 d of 1 mg of P 4 from days 3 to 6 (P 4 treatment), and (iv) 4 d of 1 mg of P 4 as in iii with one s.c. injection of 50 ng of E 2 on day 6 (P 4 E 2 treatment). All experiments reported were performed in duplicate or triplicate and repeated at least twice and usually three to five times. All procedures involving mice were conducted in accordance with National Institutes of Health regulations concerning the care and use of experimental animals. The study of mice was approved by the Albert Einstein College of Medicine. Inhibitor/agonist treatment. Inhibitors or agonists were dissolved in either PBS together with pleuronic gel, or in DMSO. In most cases, the test compound was injected intraluminally into the uterine lumen under anesthesia, 30 min before the last hormone treatment as follows: 50 μL of 10-μM rapamycin (Sigma), or 500 nM PD184352 (Tocris), or 1 μM bisindolylmaleimide I (Bis-1, CalBioChem), or 1 μM PMA (Abcam). To inhibit ESR1 signaling, 5 mg ICI182780 was injected intraperitoneally in ovariectomized mice 1 h before E 2 injection. In experiments where both ICI182780 and PMA were injected, PMA was injected 30 min after the ICI182780 followed by E 2 injection 30 min later. Mice were killed at 2 h after the last hormone injections for ERK1/2 phosphorylation assays and 8 h for phosphorylation assays of other proteins. Uterine epithelial extracts were prepared following hormone treatment as described below.
Western Blotting and Immunohistochemistry. Mice were killed at various times (0-8 h) following hormone treatment as defined by the experimental design. Their uteri were either processed for fixation for histology in 10% (vol/vol) buffered formalin or uterine epithelial cell extracts of >95% purity isolated as described (33) . Protein extracts were separated on SDS/PAGE, transferred onto Immobilon-P membranes (Millipore), and probed with antibodies against p-mTOR (Ser2448) (cat. no. 5536), p-mTOR (Ser2481) (cat. no. 2974), p-RPS6K1 (Thr389) (cat. no. 9234), p-RPS6K1 (Thr421/Ser424) (cat. no. 9204), p-RPS6 (Ser235/236) (cat. no. 2231), p-RPS6 (Ser240/244) (cat. no. 2215), p-EIF4EBP1 (Thr70) (cat. no. 9455), p-p90RSK (Ser380) (cat. no. 9335), p-ERK1/2 (Thr202/Tyr204) (cat. no. 9101), p-MARCKs (Ser152/156) (cat. no. 2741), p-GSK-3β (Ser9) (cat. no. 9323), and their corresponding total protein (mTOR, cat. no. 2983; rpS6, cat. no. 2217; EIF4EBP1, cat. no. 9644; ERK1/2, cat. no. 4695) (Cell Signaling), as well as β-tubulin (cat. no. sc-9104) (Santa Cruz Biotechnology) as internal control as described (14) . Bands were visualized following development and film exposure. The relative signals were measured by densitometry and normalized for loading with the β-tubulin intensity.
For immunohistochemistry, 5-μm transverse sections of uteri were immunostained with antibodies against BrdU (Roche) and counterstained with hematoxylin as described before (14) . The percentage of cells positive for BrdU was determined by counting positive cells versus total luminal epithelial cells in the section as described (8) .
Preparation of Stromal Cells. To obtain RNA from uterine stromal cells after intraluminal rapamycin injection, the uteri following the procedures of epithelial cell preparation as described above were incubated in 0.05% trypsin and 530 μM EDTA in PBS (HyClone) at 37°C for 30 min, followed by tissue dispersal and stromal cell preparation as described (34) . After RNA isolation as described (22) and reverse transcription using SuperScript III One-Step RT-PCR System (Invitrogen), the cDNA was used as template to determine the mRNA level of Igf1 with the forward primer: 5′-GGACCAGAGACCCTTTGC-GGG-3′ and the reverse primer: 5′-GGCTGCTTTTGTAGGCTTCAGTGG-3′ and the mRNA level of Gapdh with the forward primer: 5′-GAGCCAAACGGGT-CATCATC-3′ and the reverse primer: 5′-CCTGCTTCACCACCTTCTTG-3′.
RNA Isolation, Reverse Transcription, and Quantitative PCR. Three hours after the last hormone treatment, mice were killed, uteri removed, and total RNA was isolated as previously described (22) . RNA was subjected to reverse transcription using SuperScript III One-Step RT-PCR System (Invitrogen). The cDNA was then used as template to determine expression of PKC isoforms.
Primer sequence for PKC isoforms were: PKCα forward 5′-AAAGCAAC-CATCCAACAACC-3′ and reverse 5′-TCTCTGGGGCAATGTAGTCC-3′; PKCβI forward 5′-ATGAAACTGACCGATTTTAACTTCCTG-3′ and reverse 5′-AAGAG-TTTGTCAGTGGGAGTCAGTTCC-3′; PKCβII forward 5′-TTGTGATGG AGTATG-TGAACGGG-3′ and reverse 5′-TTAGTCTTGAATTCAGGTTTTAAAAATTC-3′; PKCδ forward 5′-CACCATCTTCCAGAAAGAACG-3′ and reverse 5′-CTTGCCA-TAGGTCCAGTTGTTG-3′; PKCe forward 5′-CATCGATCTCTCGGGATCATCG-3′ and reverse 5′-CGGTTGTCAAATGACAAGGCC-3′; PKCη forward 5′-GCATCA-ACATCCCACACAAG-3′ and reverse 5′-CGTCCTTCTTCAGCACCTTC-3′; PKCζ forward 5′-CGATGGGGTGGATGGGATCAAAA-3′ and reverse 5′-GTGTTCAT-GTCAGGGTTGTCCG-3′; PKCλ forward 5′-CGGCATGTGTAAGGAAGGAT-3′ and reverse 5′-TCCTTTGGGTCCTTGTTGAG-3′; and GAPDH forward 5′-GAGCCA-AACGGGTCATCATC-3′ and reverse 5′-CCTGCTTCACCACCTTCTTG-3′.
Determination of Protein Synthesis Rate. A total of three to five longitudinally slit uterine horns were incubated in cell culture dishes for 1 h at 37°C. The culture medium (DMEM, high glucose; HyClone) contained 8% vol/vol dialyzed FCS and 1 μCi/mL of 35 S-labeled cysteine and methionine (PerkinElmer). Epithelial extracts were prepared as described above and proteins precipitated with trichloroacetic acid with subsequent washing. Protein synthesis rates were assessed by measuring radioactive incorporation of [ 35 S] cysteine and methionine by scintillation counting as described before (35) .
Human Endometrial Biopsy and Xenotransplantation. All participants were healthy volunteers with no history of infertility, recruited from the community. Endometrial samples were collected in both proliferative and secretory phase from women within the ages of 18 and 38 (midreproductive age). Participants had not used hormonal contraception within 3 mo before study inclusion and were at least 90% normal weight for height with exclusions as described (15) . The human protocol was approved by the Committee on Clinical Investigations/Institutional Review Board and was conducted at the General Clinical Research Center at the Albert Einstein College of Medicine. Written, informed consent was obtained from all participants of this study. The biopsy samples were either subjected to paraffin sectioning (three volunteers per stage) or were xenotransplanted into host nude mouse kidney, three to five mice per sample as described (15) . Mice received 2 mg slow-releasing E 2 pellet (Innovative Research of America) through s.c. embedding, and it was removed 1 wk before hormonal regimen. The recombinant tissues were collected after either an E 2 or P 4 E 2 regimen and subjected to paraffin sectioning and immunostaining to determine phosphorylation status of mTOR and RPS6 with the phosphospecific antibodies above. Following immunohistochemistry, each cell in a given field was assessed in a "blind" manner for a value (0-3) with the following standard: 0 = no stain, 1+ = weak stain, 2+ = moderate stain, and 3+ = strong stain. These values were calculated as the H-score with the following formula: [1 × (% cells 1+) + 2 × (% cells 2+) + 3 × (% cells 3+)]. Student's t test was used to compare differences.
